新辅助纳武单抗加化疗可提高可切除NSCLC患者的总生存率

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-06-12 DOI:10.1038/s41571-025-01045-7

Peter Sidaway

{"title":"新辅助纳武单抗加化疗可提高可切除NSCLC患者的总生存率","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01045-7","DOIUrl":null,"url":null,"abstract":"Earlier data from the phase III CheckMate 816 trial led to the approval of nivolumab plus platinum-doublet chemotherapy as neoadjuvant therapy for patients with resectable non-small-cell lung cancer (NSCLC). Now, 5-year follow-up data from this trial confirm that this approach improves overall survival (OS).A total of 358 patients with stage IB–IIIA NSCLC were randomly assigned (2:1) to receive three cycles of neoadjuvant nivolumab plus chemotherapy or chemotherapy alone, followed by surgery with optional adjuvant chemotherapy and/or radiotherapy permitted in both groups. The co-primary end points (pathological complete response (pCR) rate and event-free survival (EFS)) were met at a previous cutoff; overall survival (OS) was a key secondary end point.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"61 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC\",\"authors\":\"Peter Sidaway\",\"doi\":\"10.1038/s41571-025-01045-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Earlier data from the phase III CheckMate 816 trial led to the approval of nivolumab plus platinum-doublet chemotherapy as neoadjuvant therapy for patients with resectable non-small-cell lung cancer (NSCLC). Now, 5-year follow-up data from this trial confirm that this approach improves overall survival (OS).A total of 358 patients with stage IB–IIIA NSCLC were randomly assigned (2:1) to receive three cycles of neoadjuvant nivolumab plus chemotherapy or chemotherapy alone, followed by surgery with optional adjuvant chemotherapy and/or radiotherapy permitted in both groups. The co-primary end points (pathological complete response (pCR) rate and event-free survival (EFS)) were met at a previous cutoff; overall survival (OS) was a key secondary end point.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"61 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01045-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01045-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

来自CheckMate 816 III期试验的早期数据导致nivolumab加铂双药化疗被批准为可切除的非小细胞肺癌（NSCLC）患者的新辅助治疗。现在，该试验的5年随访数据证实，这种方法提高了总生存期（OS）。共有358例IB-IIIA期NSCLC患者被随机分配（2:1），接受三个周期的新辅助纳武单抗加化疗或单独化疗，随后手术，两组均允许选择性辅助化疗和/或放疗。共同主要终点（病理完全缓解率（pCR）和无事件生存期（EFS））在前一个截止点得到满足；总生存期（OS）是一个关键的次要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC

Earlier data from the phase III CheckMate 816 trial led to the approval of nivolumab plus platinum-doublet chemotherapy as neoadjuvant therapy for patients with resectable non-small-cell lung cancer (NSCLC). Now, 5-year follow-up data from this trial confirm that this approach improves overall survival (OS).

A total of 358 patients with stage IB–IIIA NSCLC were randomly assigned (2:1) to receive three cycles of neoadjuvant nivolumab plus chemotherapy or chemotherapy alone, followed by surgery with optional adjuvant chemotherapy and/or radiotherapy permitted in both groups. The co-primary end points (pathological complete response (pCR) rate and event-free survival (EFS)) were met at a previous cutoff; overall survival (OS) was a key secondary end point.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.